| Project Name | Project Stage | Molecule Type | Molecule Source | Disease Area | Indication |
|---|---|---|---|---|---|
| GPRC5D VHH - 01 | PCC | Monoclonal | Nanobody | Hematological Malignancy | Multiple myeloma |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| BCMA/CD19 chimeric antigen receptor (CAR)-modified T cells Therapy(Peking University People's Hospital) | Phase 3 Clinical | Peking University People'S Hospital | Acquired thrombotic thrombocytopenic purpura; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antiphospholipid Syndrome; Behcet Syndrome; Carcinoma, Transitional Cell; Immunoglobulin G4-Related Disease; Lupus Erythematosus, Systemic; Myositis; Neoplasm, Residual; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Scleroderma, Systemic; Sjogren's Syndrome | Details | |
| QLS-32015 | QLS-32015; QLS32015 | Phase 3 Clinical | Qilu Pharmaceutical Co Ltd | Multiple Myeloma | Details |
| Ramantamig | JNJ-79635322; JNJ-5322 | Phase 3 Clinical | Janssen Research & Development Llc | Multiple Myeloma | Details |
| Arlocabtagene autoleucel | BMS986393; BMS-986393; CC-95266 | Phase 3 Clinical | Juno Therapeutics Inc | Multiple Myeloma | Details |
| LM-305 | LM-305 | Phase 2 Clinical | LaNova Medicines Ltd | Multiple Myeloma | Details |
| REGN-17372 | REGN17372; REGN-17372 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Multiple Myeloma | Details |
| GPRC5D/CD3 BiTEs | GPRC5D/CD3 BiTEs | Phase 2 Clinical | Institute Of Hematology & Blood Diseases Hospital | Multiple Myeloma | Details |
| BCMA/GPRC5D targeting chimeric antigen receptor T cell therapy (Essen Biotech) | Phase 2 Clinical | Essen Biotech | Multiple Myeloma | Details | |
| BCMA-GPRC5D CAR-T cells Therapy (Shenzhen University General Hospital) | Phase 2 Clinical | Shenzhen University General Hospital | Multiple Myeloma | Details | |
| CAR-T Cell Therapy(Shenzhen Geno-Immune Medical Institute) | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute, The No.2 Clinical Hospital of the Ministry of Health | Multiple Myeloma; Plasmacytoma | Details | |
| AZD-0305 | AZD0305; AZD-0305 | Phase 2 Clinical | Astrazeneca Plc | Multiple Myeloma | Details |
| Anti-GPRC5D CAR-T Cells Therapy (Shanghai YaKe Biotechnology) | Phase 2 Clinical | Shanghai YaKe Biotechnology Co Ltd | Multiple Myeloma | Details | |
| IBI-3003 | IBI3003; IBI-3003 | Phase 2 Clinical | Multiple Myeloma | Details | |
| BCMA-GPRC5D CAR-T Cells Therapy (Bio-Gene) | Phase 2 Clinical | Guangzhou Bio-Gene Technology Co Ltd | Multiple Myeloma | Details | |
| MBS-314 | MBS-314 | Phase 2 Clinical | Beijing Mabworks Biotech Co Ltd | Multiple Myeloma | Details |
| CT-071 | CT071; CT-071 | Phase 2 Clinical | CARsgen Therapeutics Holdings Ltd | Leukemia, Plasma Cell; Multiple Myeloma | Details |
| Anti-GPRC5D CAR-T Cells Therapy(Institute of Hematology & Blood Diseases Hospital) | Phase 2 Clinical | Institute Of Hematology & Blood Diseases Hospital | Multiple Myeloma | Details | |
| Anti-BCMA/GPRC5D Bispecific CAR T cell therapy (Shanghai YaKe Biotechnology) | Phase 2 Clinical | Shanghai YaKe Biotechnology Co Ltd | Multiple Myeloma | Details | |
| Ori-CAR-017 | Ori-CAR-017; GPRC5D-CAR-T | Phase 2 Clinical | OriCell Therapeutics Co Ltd | Blood Protein Disorders; Cardiovascular Diseases; Hematologic Diseases; Hemorrhagic Disorders; Hemostatic Disorders; Immune System Diseases; Immunoproliferative Disorders; Lymphoproliferative Disorders; Multiple Myeloma; Neoplasms; Paraproteinemias; Vascular Diseases | Details |
| LBL-034 | LBL-034 | Phase 2 Clinical | Nanjing Leadsbiolabs Co Ltd | Multiple Myeloma; Neoplasms | Details |
| anti-GPRC5D CAR T-cell Therapy (Dana-Farber Cancer Institute/Memorial Sloan Kettering Cancer Center/Roswell Park Comprehensive Cancer Center) | Phase 1 Clinical | Dana-Farber Cancer Institute | Multiple Myeloma | Details | |
| anti-GPRC5D CAR T-cell therapy (Bristol Myers Squibb) | Phase 1 Clinical | Bristol-Myers Squibb Company | Multiple Myeloma | Details | |
| O&D-001 | O&D-001 | Phase 1 Clinical | O&D BioTech Group Co Ltd | Multiple Myeloma | Details |
| SL-0439 | SL0439; SL-0439 | Phase 1 Clinical | Hebei Senlang Biological Technology Co Ltd | Multiple Myeloma | Details |
| TQB-2029 | TQB2029; TQB-2029 | Phase 1 Clinical | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | Multiple Myeloma | Details |
| SAR-446523 | SAR-446523 | Phase 1 Clinical | Sanofi-Aventis Gmbh | Bone Marrow Neoplasms; Multiple Myeloma | Details |
| CM-380 | CM380; CM-380 | Phase 1 Clinical | Keymed Biosciences Co Ltd | Multiple Myeloma | Details |
| OL-101 | OL-101 | Phase 1 Clinical | Overland Pharmaceuticals (Shanghai) Co Ltd | Multiple Myeloma | Details |
| QLS-4131 | QLS-4131; QLS4131 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Lupus Erythematosus, Systemic; Multiple Myeloma | Details |
| RD-140 | RD140 | Phase 1 Clinical | Nanjing Iaso Biotherapeutics Co Ltd | Leukemia, Plasma Cell; Multiple Myeloma | Details |
| Anti-GPRC5D-CD19-CAR-T cell therapy(The Second People Hospital Of Guangdong Province) | Phase 1 Clinical | The Second People Hospital Of Guangdong Province | Multiple Myeloma | Details | |
| BCMAxGPRC5D CAR-T therapy (Juno Therapeutics) | BMS-986453 | Phase 1 Clinical | Juno Therapeutics Inc | Multiple Myeloma | Details |
| SIM-0500 | SIM-0500; SIM0500 | Phase 1 Clinical | Simcere Pharmaceutical Group Ltd | Bone Marrow Neoplasms; Multiple Myeloma | Details |
| Anti-GPRC5D CAR-T Cells Therapy (Guangzhou Bio-Gene Technology Co Ltd) | Phase 1 Clinical | Guangzhou Bio-Gene Technology Co Ltd | Multiple Myeloma | Details | |
| OriC-321 | OriC-321; Ori-C-321 | Phase 1 Clinical | OriCell Therapeutics Co Ltd, Zhejiang University | Multiple Myeloma | Details |
| CAR-GPRC5D | CAR-GPRC5D; RD-118; RD118 | Phase 1 Clinical | Nanjing Iaso Biotherapeutics Co Ltd | Leukemia, Plasma Cell; Multiple Myeloma | Details |
| Forimtamig | RG-6234 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Multiple Myeloma | Details |
| MCARH-109 | Phase 1 Clinical | Eureka Therapeutics Inc, Juno Therapeutics Inc, Memorial Sloan Kettering Cancer Center | Multiple Myeloma | Details | |
| RO-7425781 | RO-7425781 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Multiple Myeloma | Details |
| Allogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cells therapy(Acellytron Therapeutics) | ACT-001(Acellytron Therapeutics) | Clinical | Acellytron Therapeutics | Multiple Myeloma | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Talquetamab | JNJ-7564; JNJ-64407564 | Approved | Genmab A/S, Johnson & Johnson Innovative Medicine | TALVEY, 拓立珂 | United States | Multiple Myeloma | Janssen Biotech Inc | 2023-08-09 | Hematologic Neoplasms; Multiple Myeloma | Details |
